NP和GP方案治疗晚期非小细胞肺癌疗效分析

目的:评价NP和GP两组化疗方案治疗晚期非小细胞肺癌(nonsmallcelllungcancer,NSCLC)的疗效和不良反应。方法:将有明确的病理学和(或)细胞学诊断的63例晚期NSCLC患者分为两组,NP组33例,国产长春瑞滨(盖诺,NVB)25mg/m2,静脉推注,d1、d8;顺铂(DDP)80～90mg/m2,静脉滴入,d1;GP组30例,吉西他滨(健择,GEM)1.25g/m2,静脉滴入,d1、d8;DDP80～90mg/m2,静脉滴入,d1。两组同时配合水化利尿,每21d为1个周期,化疗3个周期后评价疗效,化疗期间记录不良反应。结果:NP与GP方案的有效率分别为36.3%和40.0%,中位生存时间分别为12.2和12.0个月,1年生存率分别为47.2%和43.5%,2年生存率分别为21.1%和17.8%。不良反应主要为血液学毒性和恶心、呕吐。结论:NP和GP两组化疗方案在治疗晚期NSCLC的近期疗效、中位生存期、1年和2年生存率方面相近,化疗不良反应可耐受。

Clinical research of combined chemotherapy of vinorelbine plus cisplatin and gemcitabine plus cisplatin in treatment of advanced non-small cell lung cancer

OBJECTIVE:To evaluate the effect and adverse reactions of combination chemotherapy of vinorelbine plus cisplatin and gemcitabine plus cisplatin in the treatment of advanced non-small cell lung cancer. METHODS: Sixty-three cases of pathologically and/or cytologically conformed advanced NSCLC were enrolled: 33 received NP regimen(vinorelbine 25 mg/m2 iv. d_ 1,8;DDP 80-90 mg/m2 iv.drip.d_1.combined with diureses); 30 received GP regimen (gemcitabine 1.25/m2 iv.drip.d_ 1,8;DDP 80-90 mg/m2 iv.drip.d_1.combined with diureses) and 21 days as 1 cycle. Tumor assessment was done after 3 cycles and adverse reactions were recorded as chemotherapy. RESULTS: Among 33 cases, the overall response rates (CR+PR) were 36.3% and 40.0%, the median survival time was 12.2 months and 12.0 months, and the 1-year and 2-year survival rates were 47.2% and 43.5%,21.1%and 17.8% respectively. The major adverse reactions were hematology toxicity, nausea and vomiting. CONCLUSIONS: The combined chemotherapy including vinorelbine and cisplatin is effective and tolerant in the treatment of advanced non-small cell lung cancer.